Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
European Journal of Pediatrics
Erschienen in: European Journal of Pediatrics 3/2009

01.03.2009 | Review

Saccharomyces boulardii in childhood

verfasst von: Yvan Vandenplas, Oscar Brunser, Hania Szajewska

Erschienen in: European Journal of Pediatrics | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Probiotics are live microorganisms which confer a health benefit on the host. Saccharomyces boulardii, a yeast, has been found to be an effective probiotic in double-blind placebo-controlled randomized clinical studies.

Materials and methods

We reviewed the established mechanisms of actions and clinical efficacy in children of S. boulardii.

Conclusions

The mechanisms of action of S. boulardii depend mainly on the inhibition of some bacterial toxins, anti-inflammatory effects, and on stimulating effects on the intestinal mucosa such as trophic effects on the brush border enzymes and immunostimulatory effects. At present, in pediatric populations, there is evidence that S. boulardii is beneficial for the treatment of acute gastroenteritis and the prevention of antibiotic-associated diarrhea. More data are needed in other indications such as traveller’s diarrhea, Helicobacter pylori eradication, and inflammatory bowel disease. S. boulardii is a yeast strain that has been extensively studied in vitro and in vivo. Recent data have opened the door for new therapeutic indications.
Literatur
1.
Andersson H, Asp NG, Bruce A et al (2001) Health effects of probiotics and prebiotics. A literature review on human studies. Scand J Nutr 45:58–95
2.
Barbut F, Meynard JL, Guiguet M et al (1997) Clostridium difficile-associated diarrhea in HIV infected patients: epidemiology and risk factors. J Acq Immun Def Synd 16:176–181
3.
Bartlett JG, Chang TW, Gurwith M et al (1978) Antibiotic-associated pseudomembranous colitis due to toxin producing Clostridia. N Engl J Med 298:531–534PubMed
4.
Bartlett JG (2002) Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 346:334–339PubMedCrossRef
5.
Bassetti S, Frei R, Zimmerli W (1998) Fungemia with Saccharomyces cerevisiae after treatment with S. boulardii. Am J Med 105:71–72PubMedCrossRef
6.
Baumgart D (2007) The probiotic yeast Saccharomyces boulardii inhibits DC-induced activation of naïve T-cells. Gastroenterology 135(4):A–559 (sup 1)
7.
Benhamou PH, Berlier P, Danjou G et al (1999) Antibiotic-associated diarrhoea in children: a computer monitored double-blind outpatients trial comparing a protective and a probiotic agent. Med Chir Dig 28:163–168
8.
Bernet MF, Brassart D, Neeser JR et al (1994) Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 35:483–489PubMedCrossRef
9.
Bhatia SJ, Kochar N, Abraham P et al (1989) Lactobacillus acidophilus inhibits growth of Campylobacter pylori in vitro. J Clin Microbiol 27:2328–2330PubMed
10.
Billoo AG, Memon MA, Khaskheli SA, Murtaza G, Iqbal K, Saeed Shekhani M, Siddiqi AQ (2006) Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World J Gastroenterol 12:4557–4560PubMed
11.
Bléhaut H, Massot J, Elmer GW et al (1989) Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm Drug Dispos 10:353–364PubMedCrossRef
12.
Breves G, Faul K, Schröder B et al (2000) Application of the colon-stimulation technique for studying the effects of Saccharomyes boulardii on basic parameters of porcine cecal microbial metabolism disturbed by Clindamycin. Digestion 61:193–200PubMedCrossRef
13.
Brunser O (2009) Coincubation of Saccharomyces boulardii with Helicobacter pylori. A Morphological Study (in press)
14.
Burkhardt O, Köhnlein T, Pletz M et al (2005) Saccharomyces boulardii induced sepsis: successful therapy with voriconazole after treatment failure with fluconazole. Scand J Infect Dis 37:69–72PubMedCrossRef
15.
Buts JP, Bernasconi P, Vaerman JP et al (1990) Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 35:251–256PubMedCrossRef
16.
Buts JP, Bernasconi P, Van Craynest MP et al (1986) Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res 20:192–196PubMedCrossRef
17.
Buts JP, Corthier G, Delmee M (1993) Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. J Pediatr Gastroenterol Nutr 16:419–425PubMed
18.
Buts JP, De Keyser N, De Raedemaeker L (1994) Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines. Pediatr Res 36:522–527PubMedCrossRef
19.
Buts JP, Duranton B, De Keyser N et al (1998) Premature stimulation of rat sucrase-isomaltase (SI) by exogenous insulin and the analog B-Asp10 is regulated by a receptor-mediated signal triggering SI gene transcription. Pediatr Res 43:585–591PubMedCrossRef
20.
Buts JP, De Keyser N, Marandi S et al (1999) Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats. Gut 45:89–96PubMed
21.
Buts JP, De Keyser N, Stilmant C et al (2002) Saccharomyces boulardii enhances N-terminal peptide hydrolysis in suckling rat small intestine by endoluminal release of a zinc-binding metalloprotease. Pediatr Res 51:528–534PubMedCrossRef
22.
Buts JP, Dekeyser N, Stilmant C et al (2006) Saccharomyces boulardii produces in rat small intestine a novel protein phosphatase that inhibits Escherichia coli endotoxin by dephosphorylation. Pediatr Res 60:24–29PubMedCrossRef
23.
Canani RB, Cirillo P, Terrin GA et al (2007) Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ 335:340–347PubMedCrossRef
24.
Castagliuolo I, LaMont JT, Nikulasson ST et al (1996) Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 12:5225–5232
25.
Castagliuolo I, Riegler MF, Valenick L et al (1999) Saccharomyces boulardii protease mediates Clostridium difficile toxin A and B effects in human colonic mucosa. Infect Immun 67:302–307PubMed
26.
Castaneda C, Garcia E, Santa Cruz M, Fernandez M, Monterrey P (1995) Effects of Saccharomyces boulardii in children with chronic diarrhea, especially cases due to giardiasis. Rev Mex Pueric Pediatr 2:12–16
27.
Cetina-Sauri G, Busto GS (1994) Therapeutic evaluation of Saccharomyces boulardii in children with acute diarrhea. Ann Ped 6:397–400
28.
Cindoruk M, Erkan G, Karakan T et al (2007) Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 12:309–316PubMedCrossRef
29.
Czerucka D, Dahan S, Mograbi B et al (2000) Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infect Immun 68:5998–6004PubMedCrossRef
30.
Czerucka D, Piche T, Rampal P (2007) Review article: yeast as probiotics—Saccharomyces boulardii. Aliment Pharmacol Ther 26:767–778PubMed
31.
Czerucka D, Rampal P (2002) Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes Infect 4:733–739PubMedCrossRef
32.
Czerucka D, Roux I, Rampal P (1994) Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3′, 5′-cyclic monophosphate induction in intestinal cells. Gastroenterology 106:65–72PubMed
33.
Dahan S, Dalmasso G, Imbert V et al (2003) Saccharomyces boulardii interfers with enterohemorragic Escherichia coli-induced signaling pathways in T84 cells. Infect Immun 71:766–773PubMedCrossRef
34.
Dalmasso G, Cottrez F, Imbert V et al (2006) Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 131:1812–1825PubMedCrossRef
35.
Dalmasso G, Loubat A, Dahan S et al (2006) Saccharomyces boulardii prevents TNF-alpha-induced apoptosis in EHEC-infected T84 cells. Res Microbiol 157:456–465PubMedCrossRef
36.
de Llanos R, Querol A, Pemán J et al (2006) Food and probiotic strains from the Saccharomyces cerevisiae species as a possible origin of human systemic infections. Int J Food Microbiol 110:286–289PubMedCrossRef
37.
Desreumeaux P, Rousseaux C (2006) Influence of the intestinal microflora on host immunity in inflammatory bowel disease. In G. Microflora Ed. John Libbey Eurotext
38.
Duman DG, Bor S, Ozütemiz O et al (2005) Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 17:1357–1361PubMedCrossRef
39.
Elmer GW, Corthier G (1991) Modulation of Clostridium difficile induced mortality as a function of the dose and the viability of the Saccharomyces boulardii used as a preventative agent in gnotobiotic mice. Can J Microbiol 37:315–317PubMed
40.
Elmer GW, McFarland LV, Surawicz CM et al (1999) Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther 13:1663–1668PubMedCrossRef
41.
Elmer GW, Moyer KA, Vega R et al (1995) Evaluation of Saccharomyces boulardii for patients with HIV-related chronic diarrhoea and in healthy volunteers receiving antifungals. Microecol and Ther 25:23–31
42.
Elstner CL, Lindsay AN, Book LS et al (1983) Lack of relationship of Clostridium difficile to antibiotic-associated diarrhea in children. Pediatr Inf Dis 2:364–366
43.
Erdeve O, Tiras U, Dallar Y (2004) The probiotic effect of Saccharomyces boulardii in a pediatric age group. J Trop Pediatr 50:234–236PubMedCrossRef
44.
45.
Fietto JLR, Araújo RS, Valadão FN et al (2004) Molecular and physiological comparisons between Saccharomyces cerevisiae and Saccharomyces boulardii. Can J Microbiol 50:615–621PubMedCrossRef
46.
Gaon D, Garcia H, Winter L et al (2003) Effect of Lactobacillus strains and Saccharomyces boulardii on persistent diarrhea in children. Medicina (B Aires) 63:293–298
47.
Gedek BR (1999) Adherence of Escherichia coli serogroup O 157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii. Mycoses 42:261–264PubMedCrossRef
48.
Geyik MF, Aldemir M, Hosoglu S et al (2006) The effects of Saccharomyces boulardii on bacterial translocation in rats with obstructive jaundice. Ann R Coll Surg Engl 88:176–180PubMedCrossRef
49.
Girard P, Pansart Y, Lorette I et al (2003) Dose–response relationship and mechanism of action of Saccharomyces boulardii in castor oil-induced diarrhea in rats. Dig Dis Sci 48:770–774PubMedCrossRef
50.
Goldman CG, Barrado DA, Balcarce N et al (2006) Effect of a probiotic food as an adjuvant to triple therapy for eradication of Helicobacter pylori infection in children. Nutrition 22:984–988PubMedCrossRef
51.
Gotteland M, Poliak L, Cruchet S et al (2005) Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori. Acta Paediatr 94:1747–1751PubMedCrossRef
52.
Graf C, Gavazzi G (2007) Saccharomyces cerevisiae fungemia in an immunocompromised patient not treated with Saccharomyces boulardii preparation. J Infect 54:310–311PubMedCrossRef
53.
Guarino A, Albano F, Ashkenazi S et al (2008) The ESPGHAN/ESPID Guidelines for the Management of Acute Gastroenteritis in Children in Europe. J Pediatr Gastroenterol Nutr 46:S81–S122PubMedCrossRef
54.
Hafeez A, Tariq P, Ali S et al (2002) The efficacy of Saccharomyces boulardii in the treatment of acute watery diarrhea in children: a multicentre randomized controlled trial. J Coll Phys Surg Pakist 12:432–434
55.
Hennequin C, Kauffman-Lacroix C, Jobert A et al (2000) Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Diseases 19:16–20CrossRef
56.
Hennequin C, Thierry A, Richard GF et al (2001) Microsatellite typing as a new tool for identification of Saccharomyces cerevisiae strains. J Clin Microbiol 39:551–559PubMedCrossRef
57.
Herek O, Kara IG, Kaleli I (2004) Effects of antibiotics and Saccharomyces boulardii on bacterial translocation in burn injury. Surg Today 34:256–260PubMedCrossRef
58.
Htwe K, Yee KS, Tin M, Vandenplas Y (2008) Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study. Am J Trop Med Hyg 78:214–216PubMed
59.
60.
Jawhara S, Poulain D (2007) Saccharomyces boulardii decreases inflammation and intestinal colonization by Candida albicans in a mouse model of chemically-induced colitis. Med Mycol 45:691–700PubMedCrossRef
61.
Klein SM, Elmer GW, McFarland LV et al (1993) Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharm Res 10:1615–1619PubMedCrossRef
62.
Kotowska M, Albrecht P, Szajewska H (2005) Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 21:583–590PubMedCrossRef
63.
Kurugol Z, Koturoglu G (2005) Effects of Saccharomyces boulardii in children with acute diarrhoea. Acta Paediatr 94:44–47PubMedCrossRef
64.
Lionetti E, Miniello VL, Castellaneta SP et al (2006) Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. Aliment Pharmacol Ther 24:1461–1468PubMedCrossRef
65.
Luyer MD, Buurman WA, Hadfoune M et al (2005) Strain-specific effects of probiotics on gut barrier integrity following hemorrhagic shock. Infect Immun 73:3686–3692PubMedCrossRef
66.
Mathur S, Singh R (2005) Antibiotic resistance in food lactic acid bacteria—a review. Int J Food Microbiol 105:281–295PubMedCrossRef
67.
McFarland LV, Surawicz CM, Stamm WE (1990) Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 162:678–684PubMed
68.
McFarland LV (1998) Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis 16:292–307PubMedCrossRef
69.
Mumy KL, Chen X, Kelly CP et al (2008) Saccharomyces boulardii interferes with Shigella pathogenesis by postinvasion signaling events. Am J Physiol Gastrointest Liver Physiol 294:G599–G609PubMedCrossRef
70.
Muñoz P, Bouza E, Cuenca-Estrella M et al (2005) Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 40:1625–1634PubMedCrossRef
71.
Piechno S, Seguin P, Gangneux JP (2007) Saccharomyces boulardii fungal sepsis: beware of the yeast. Can J Anaesth 54:245–246PubMedCrossRef
72.
Pothoulakis C, Kelly CP, Joshi MA et al (1993) Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 104:1108–1115PubMed
73.
Riedel BD, Ghishan FK (1996) Acute diarrhea. In: Walker WA, Durie PR, Hamilton JR, Walker-Smith JA, Watkins JB (eds) Pediatric gastrointestinal disease, 2nd edn. Mosby-Year Book Inc., St. Louis, pp 251–262
74.
Rigothier MC, Maccario J, Vuong PN et al (1990) Effects of Saccharomyces boulardii yeast on trophozoites of Entamoeba histolytica in vitro and in cecal amebiasis in young rats. Ann Parasitol Hum Comp 65:51–60PubMed
75.
Rijnders BJA, Van Wijngaerden E, Verwaest C et al (2000) Saccharomyces fungemia complicating S. boulardii treatment in a non-immunocompromised host. Intensive Care Med 26:825PubMedCrossRef
76.
Rodrigues ACP, Nardi RM, Bambirra EA et al (1996) Effect of Saccharomyces boulardii against experimental oral infection with Salmonella typhimurium and Shigella flexneri conventional and gnotobiotic mice. J Appl Bacteriol 91:251–256
77.
Schneider SM, Girard-Pipau F, Filippi J et al (2005) Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition. World J Gastroenterol 11:6165–6169PubMed
78.
Sougioultzis S, Simeonidis S, Bhaskar KR et al (2006) Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun 343:69–76PubMedCrossRef
79.
Sykora J, Valeckova K, Amlerova J et al (2005) Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114 001 and the eradication of H. pylori in children: a prospective randomized double-blind study. J Clin Gastroenterol 39:692–698PubMedCrossRef
80.
Szajewska H, Setty M, Mrukowicz J et al (2006) Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. J Pediatr Gastroenterol Nutr 42:454–475PubMedCrossRef
81.
Szajewska H, Skórka A, Dylag M (2007) Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Aliment Pharmacol Ther 25:257–264PubMed
82.
Temmerman R, Pot B, Huys G et al (2003) Identification and antibiotic susceptibility of bacterial isolates from probiotic products. Int J Food Microbiol 81:1–10PubMedCrossRef
83.
Tong JL, Ran ZH, Shen J et al (2007) Meta-analysis: the effect of supplementation with probiotics on eradication rates and side effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 25:155–168PubMedCrossRef
84.
Turck D, Bernet JP, Marx J et al (2003) Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr 37:22–26PubMedCrossRef
85.
Vandenplas Y, Salvatore S, Vieira M et al (2007) Probiotics in infectious diarrhoea in children: are they indicated? Eur J Pediatr 166:1211–1218PubMedCrossRef
86.
Villarruel G, Rubio DM, Lopez F et al (2007) Saccharomyces boulardii in acute childhood diarrhea: a randomized controlled study. Acta Paediatr 96:538–541PubMedCrossRef
87.
WHO (2003) The treatment of diarrhoea. A manual for physicians and other senior health workers. WHO/CAH/03.7 10/03
88.
WHO (1995) The treatment of diarrhea. A manual for physicians and other senior health workers; WHO/CDR/95.3. Geneva, World Health Organization
89.
Wiström J, Norrby SR, Myhre EB et al (2001) Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 47:43–50PubMedCrossRef
90.
Wu X, Vallance BA, Boyer L et al (2008) Saccharomyces boulardii ameliorates Citrobacter rodentium-induced colitis through actions on bacterial virulence factors. Am J Physiol Gastrointest Liver Physiol 294:G295–G306PubMedCrossRef
91.
Zunic P, Lacotte J, Pegoix M et al (1991) S. boulardii fungemia. Apropos of a case. Therapie 46:498–499PubMed
Metadaten
Titel
Saccharomyces boulardii in childhood
verfasst von
Yvan Vandenplas
Oscar Brunser
Hania Szajewska
Publikationsdatum
01.03.2009
Verlag
Springer-Verlag
Erschienen in
European Journal of Pediatrics / Ausgabe 3/2009
Print ISSN: 0340-6199
Elektronische ISSN: 1432-1076
DOI
https://doi.org/10.1007/s00431-008-0879-7

Weitere Artikel der Ausgabe 3/2009

European Journal of Pediatrics 3/2009 Zur Ausgabe

Letter to the Editor

Reply to correspondence letter by Jae Il Shin and Jae Seung Lee: Bartter syndrome and cholelithiasis in an infant: is this a mere coincidence?

Short Report

Transition from insulin to sulfonylurea in a child with diabetes due to a mutation in KCNJ11 encoding Kir6.2—initial and long-term response to sulfonylurea therapy

Original Paper

Does diagnostic delay result in decreased survival in paediatric brain tumours?

Short Report

A case of Listeria meningoencephalitis complicated by hydrocephalus in an immunocompetent infant

Original Paper

Tracheobronchial anatomy and the distribution of inhaled foreign bodies in children

Original Paper

Clinical and molecular genetic findings in a 6-year-old Bosnian boy with triple A syndrome

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

23.04.2024 Typ-1-Diabetes Nachrichten

Wenn Kinder an Werktagen zum Arzt gehen, werden neu auftretender Typ-1-Diabetes und diabetische Ketoazidosen häufiger erkannt als bei Arztbesuchen an Wochenenden oder Feiertagen.

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

22.04.2024 Fehlsichtigkeit Nachrichten

Augentropfen mit niedrig dosiertem Atropin können helfen, das Fortschreiten einer Kurzsichtigkeit bei Kindern zumindest zu verlangsamen, wie die Ergebnisse einer aktuellen Studie mit verschiedenen Dosierungen zeigen.

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

18.04.2024 Spinale Muskelatrophien Nachrichten

Seit 2021 ist die Untersuchung auf spinale Muskelatrophie Teil des Neugeborenen-Screenings in Deutschland. Eine Studie liefert weitere Evidenz für den Nutzen der Maßnahme.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise